SPOTLIGHT: Arimidex wins new indication

AstraZeneca's Arimidex has been granted a new indication by the UK's Medicines and Healthcare products Regulatory Agency. The new indication "will mean that more postmenopausal women whose breast cancer is fueled by the hormone, oestrogen -- about 75 percent of all postmenopausal cases -- are now eligible to receive Arimidex after surgery to prevent their disease returning." Story

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.